Free Newsletter
Genetic variation found for IBD
A research team has found a gene that plays a role in inflammatory bowel disease (IBD), a development that could point the way to new therapies for a medical condition that afflicts more than one million people in the United States. Long associated with Ashkenazi Jews, IBD is responsible for Crohn's disease and colitis. A variety of intestinal symptoms along with skin ulcers and eye conditions are linked to IBD. By comparing single nucleotide polymorphisms in Jewish and non-Jewish populations, they found that the protein receptor interleukin-23 was different in people with IBD. Scientists believe that a considerable amount of new research into IL-23 implicates the variation as a trigger for a variety of inflammations. A coding variant, though, can help protect people from inflammation, which could be the key to discovering a new therapeutic.
- here's The New York Times article
Related Article:
Crohn's data indicates long-term Tysabri benefits. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: